Thus, the humanised antibody trastuzumab, which recognises the extracellular domain of HER2, upregulates miR‐194 expression in two HER2‐positive breast cancer cell lines 113, and miR‐194 suppresses cell migration reportedly via downregulation of talin2. Here, ERBB2 is linked to breast cancer.